Model‐Informed Reverse and Forward Translation of Safety Risks in Drug Development

E-ISSN： 1532-6535|103|2|199-201

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.103, Iss.2, 2018-02, pp. : 199-201

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reverse and Forward Translational Neuropharmacology in Psychiatric Drug Discovery

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 193-195

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 196-198

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 224-232

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug Development (and Academic Medicine): Charting the Course Forward

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 5, 2014-11 ,pp. : 519-522

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reverse Translation for Assessment of Confidence in Animal Models of Multiple Sclerosis for Drug Discovery

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 262-270

John Wiley & Sons Inc

Access to resources Recommend Favorite